the sun malaysia ipaper logo 150x150
Friday, July 3, 2026
28.6 C
Kuala Lumpur
the sun malaysia ipaper logo 150x150

2,579 dengue cases, three deaths reported in ME13 – Health DG

PUTRAJAYA: During the 13th Epidemiological Week (ME13), from March 24 to March 30, a total of 2,579 cases of dengue fever were reported, showing a decline from the previous week’s 3,041 cases.

Health director-general, Datuk Dr. Muhammad Radzi Abu Hassan, noted that within this timeframe, three deaths resulting from complications of dengue fever were also recorded.

“The cumulative reported cases of dengue fever up to ME13 amounted to 44,144 cases, compared to 28,587 cases for the same period in 2023.

“Additionally, there were 31 deaths due to dengue fever complications, compared to 18 deaths during the same period last year.

Dr. Radzi highlighted in today’s statement that there were 135 reported hotspot localities during ME13, with 114 localities in Selangor, 10 in Kuala Lumpur and Putrajaya, five in Penang, four in Negeri Sembilan, and two in Kedah,” he said in a statement today.

In terms of chikungunya, no cases were identified during surveillance in ME13, maintaining the cumulative total at 13 cases without any reported outbreaks, he said.

Regarding zika, Dr. Radzi indicated that screening was carried out on 621 blood samples and one urine sample, all returning negative results.

STAY AHEAD OF THE CURVE

Join our community for instant updates and exclusive content.

Join Telegram Channel

Related


spot_img

Latest News

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations

TAIPEI, TAIWAN - Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX) including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US $122.5 million through its wholly owned subsidiary Bora Biologics USA, LLC.. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics.

Most Viewed

spot_img
WC26

World Cup 2026

Updates, Fixtures, Results & Standings